Then, we analyzed the correlations of M2 macrophage with the clinical characteristics of GBM patients and found that the M2 macrophage signature (CD206) was significantly upregulated, whereas M1 marker CD80 was downregulated in GBM patients with bigger tumor volume (>4 cm) (Figures 1(e) and 1(f)) and higher WHO grade (WHO III/IV) (Figures 1(g) and 1(h)), but their expressions had nothing to do with patients' gender (Supplementary Figure S1A, B) and age (Supplementary Figure S1C, D), indicating that the enrichment of M1 and M2 macrophages was relevant to GBM progression. This evidence concerns the gene CD80 and neoplasm.